We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Digital Test Accurately Predicts Ovulation

By LabMedica International staff writers
Posted on 14 Jul 2011
A digital ovulation test consists of a digital reader and urine test sticks, which detects the surge in luteinising hormone (LH) that triggers ovulation.

The popular calendar method predicted ovulation correctly in only one in four women, whereas the ClearBlue Digital Ovulation test (20-test pack) predicted ovulation correctly in 99% of women over the same period.

Dr. More...
Jayne Ellis, director of scientific and medical affairs at SPD Swiss Precision Diagnostics (Geneva, Switzerland), makers of the test, explained, "The test stick is held in the urine stream and if the LH levels are elevated, a smiley face appears on the screen. This indicates that the woman is in a highly fertile phase. If there is no hormone surge, a circle is shown on the screen and the woman can test again the following day."

The calendar method, which uses the previous cycle length and subtracts 14 or 15 days to give an estimate of the day of ovulation, is the most commonly used technique for predicting fertility. Available on many websites and mobile phone applications, it is used by 35% of those attempting to conceive. However, up until now it had not been subjected to scientific scrutiny, said Dr. Ellis.

A comparative analysis of the two methods, the calendar and the Clearblue Digital Ovulation test, examined a group of 101 women recruited via local press adverts and a website.

The accuracy with which the two test methods predicted the peak fertile days with the standard laboratory method was compared. "We found that the calendar method was inaccurate in predicting ovulation, and therefore the peak fertile days," said Dr. Ellis. "This is because it uses data from previous cycles which are naturally variable in many women."

Use of the calendar method in women trying to conceive resulted in only one third of cycles where peak fertile days were correctly predicted. On an individual basis, only one in four women trying to conceive would have correctly identified their peak fertile days using the calendar method. In 48% of cycles, the peak fertile period was identified by this method after it had occurred.

By contrast, the Clearblue tests would have been conducted on the day of the LH surge in 77% of the cycles if a seven-stick pack had been used and start day was based on average cycle length. In 6% of cycles, the surge had occurred before the first test day, and in 17% of cycles, it had occurred after the last test was conducted. However, if a 20-stick pack was used, a test would have been conducted on the day of the LH surge in 99% of cycles.

"Like the calendar method, our test is safe and noninvasive," said Dr. Ellis. "But the difference is that it predicts ovulation accurately and therefore gives couples who want to get pregnant the chance to time intercourse correctly and maximize the chances of conception."

The study was presented at the Annual European Society of Human Reproduction and Embryology Conference, which took place in Stockholm, Sweden on July 5-6, 2011.

Related Links:

Swiss Precision Diagnostics



New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Collection and Transport System
PurSafe Plus®
New
Homocysteine Quality Control
Liquichek Homocysteine Control
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The VITROS hs Troponin I Assay is designed for use on VITROS Systems (Photo courtesy of QuidelOrtho)

High-Sensitivity Troponin I Assay Aids in Diagnosis of Myocardial Infarction

Heart disease remains the leading cause of death for adults over 45 in the United States, accounting for nearly one in three deaths. In 2023 alone, 919,032 Americans died from cardiovascular disease —... Read more

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.